Sprenger, Jana

[["dc.bibliographiccitation.firstpage","435"],["dc.bibliographiccitation.issue","4_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","435"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Conradi, L."],["dc.contributor.author","Bleckmann, A."],["dc.contributor.author","Schirmer, M."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Homayounfar, K."],["dc.contributor.author","Wolff, H. A."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Ghadimi, B. M."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:57:19Z"],["dc.date.available","2022-06-08T07:57:19Z"],["dc.date.issued","2011"],["dc.description.abstract","435 Background: Fluorouracil (5FU) remains the backbone of neoadjuvant radiochemotherapy (RCT) as well as adjuvant therapeutic strategies in multimodal treatment of rectal cancer patients. Due to its central role as the major target of 5FU thymidylate synthase (TS) is a promising biomarker in rectal cancer. We assessed TS in 208 patients with regard to its predictive/prognostic capacity for disease free DFS and overall cancer specific survival (CSS). Methods: 167 patients cUICC stages II (28%) and III (72%) received preoperative 5FU based RCT followed by total mesorectal excision (TME) A comparison group n = 41 received postoperative RCT after primary TME. All patients were treated after standardized protocols within phase-II/-III trials of the German Rectal Cancer Study Group. TS levels from pretreatment biopsies and corresponding resection specimens were assessed by immunohistochemical staining for their impact on DFS and CSS. Additionally, a TS gene polymorphism (28 bp repeat) was analysed in respect to intracellular protein expression levels and prognostic significance. Results: Patients with low TS expression in pre-treatment biopsies showed a correlation with impaired CSS (p = 0.015). After neoadjuvant RCT there was evidence of lymph node metastases ypUICC stage III in 32.6%. Complete histopathologically confirmed tumor regression TRG 4 was achieved in 16 patients (9.5%). During follow-up (median 57 months) patients with low intratumoral TS expression and positive nodal status were at high risk for local and/or distant metastatic recurrence (p = 0.040). Analysis of the 28bp repeat revealed a correlation of 3/ 3 genotype with high TS expression in pretherapeutical biopsies (p = 0.05). Conclusions: TS represents a prognostic biomarker in locally advanced rectal cancer indicating an unfavourable outcome for patients with low TS expression and might help to adapt adjuvant therapy regimens by stratifying patients according to their risk for cancer recurrence. No significant financial relationships to disclose."],["dc.identifier.doi","10.1200/jco.2011.29.4_suppl.435"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110056"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.eissn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Biomarker study in rectal cancer patients after 5FU-based radiochemotherapy: Evaluation of the prognostic capacity of thymidylate synthase in pretreatment biopsies and resected adenocarcinoma."],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S430"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.volume","47"],["dc.contributor.author","Conradi, L.C."],["dc.contributor.author","Bleckmann, A."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Schirmer, M."],["dc.contributor.author","Homayounfar, K."],["dc.contributor.author","Wolff, H.A."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Ghadimi, B.M."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:58:33Z"],["dc.date.available","2022-06-08T07:58:33Z"],["dc.date.issued","2011"],["dc.identifier.doi","10.1016/S0959-8049(11)71771-3"],["dc.identifier.pii","S0959804911717713"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110450"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.issn","0959-8049"],["dc.title","6126 POSTER Thymidylate Synthase as Biomarker in Rectal Cancer Patients After 5-FU-based Radiochemotherapy – Evaluation of the Prognostic Capacity in Pre-treatment Biopsies and Resected Adenocarcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S431"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.volume","47"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Rödel, F."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Conradi, L.C."],["dc.contributor.author","Yildirim, M."],["dc.contributor.author","Ghadimi, B.M."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Rödel, C."],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:58:33Z"],["dc.date.available","2022-06-08T07:58:33Z"],["dc.date.issued","2011"],["dc.identifier.doi","10.1016/S0959-8049(11)71775-0"],["dc.identifier.pii","S0959804911717750"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110451"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.issn","0959-8049"],["dc.title","6130 POSTER Survivin Expression in Rectal Cancer During Preoperative Radiochemotherapy and Its Impact on Metastasis and Patients' Survival"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e14115"],["dc.bibliographiccitation.issue","15_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","e14115"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Rodel, F."],["dc.contributor.author","Rothe, H."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Conradi, L."],["dc.contributor.author","Ghadimi, B. M."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Rödel, C."],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:57:18Z"],["dc.date.available","2022-06-08T07:57:18Z"],["dc.date.issued","2010"],["dc.identifier.doi","10.1200/jco.2010.28.15_suppl.e14115"],["dc.identifier.isi","000208852000619"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110052"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.eissn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Survivin: A potential predictive and prognostic marker in multimodal rectal cancer therapy."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","483"],["dc.bibliographiccitation.issue","4_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","483"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Rödel, F."],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Conradi, L."],["dc.contributor.author","Homayounfar, K."],["dc.contributor.author","Ghadimi, B. M."],["dc.contributor.author","Yildrim, M."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Rödel, C."],["dc.contributor.author","Liersch, T."],["dc.date.accessioned","2022-06-08T07:57:19Z"],["dc.date.available","2022-06-08T07:57:19Z"],["dc.date.issued","2011"],["dc.description.abstract","483 Background: Valid molecular markers need to be implemented in clinical trials to fulfill the demand of a risk-adapted and more individualized multimodal therapy of locally advanced primary rectal cancer. In the present study the expression of the inhibitor-of-apoptosis (IAP) protein Survivin was evaluated in pre-treatment biopsies and corresponding post-treatment resection specimens, and was correlated to histo-pathological tumor characteristics and clinical follow-up. Methods: 116 patients with stage II/III rectal cancer treated with 5-FU-based neoadjuvant radiochemotherapy (RCT) within the German Rectal Cancer Trials were investigated. Survivin expression in pre-treatment biopsies and surgical resection specimens were determined by immunohistochemistry by two independent institutions and correlated with histopathologic parameters, tumor recurrences, disease-free and overall cancer-specific survival. Results: In pre-treatment biopsies, a higher Survivin expression correlated with advanced ypT (p=0.026) and ypUICC (p=0.05) stage as well as decreased disease-free survival (p=0.038) after preoperative RCT. High post-treatment Survivin levels were associated with advanced ypT stage (p=0.03) and residual lymph node metastases (p=0.04). Moreover, neoadjuvant RCT resulted in a significant down-regulation of Survivin expression (p < 0.0001). A failure of RCT-induced down-regulation was associated with development of distant metastases (p=0.0056) and cancer-related death (p=0.026), and was significantly correlated with disease-free (p=0.011 /0.02 ) and cancer-specific survival (p=0.0017 /0.01 ) in uni - and multivariate analyses. Conclusions: Survivin expression displays a marker with prognostic validity in rectal cancers. These results underline the usefulness of Survivin to monitor individual response to RCT in rectal cancer, and encourage anti-Survivin strategies in multimodal rectal cancer therapy within future randomised clinical trials. No significant financial relationships to disclose."],["dc.identifier.doi","10.1200/jco.2011.29.4_suppl.483"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/110057"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-575"],["dc.relation.eissn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Association of survivin expression following neoadjuvant radiochemotherapy in rectal cancer with distant metastases and survival."],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","779"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Der Onkologe"],["dc.bibliographiccitation.lastpage","788"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Becker, H."],["dc.contributor.author","Ghadimi, B. Michael"],["dc.date.accessioned","2018-11-07T08:41:01Z"],["dc.date.available","2018-11-07T08:41:01Z"],["dc.date.issued","2010"],["dc.description.abstract","Based on the results of the CAO/ARO/AIO-94 trial of the German Rectal Cancer Study Group preoperative 5-FU-based radiochemotherapy (RCTx) is recommended as the standard treatment of locally advanced rectal cancers (UICC stages II and III) of the middle and lower third of the rectum (0-12 cm above the anocutaneous margin). Unfortunately, tumor response to neoadjuvant RCTx is very heterogeneous ranging from complete pathological response (pCR) to total resistance. To fulfill the clinical requirement of an individualized and risk-adapted multimodal treatment, progress has been made in genomic and proteomic analyses of cellular signaling pathways. Compared with postoperatively determined clinicopathological parameters of local response, complex phenotypes, such as tumor responsiveness to RCTx do not depend on the expression levels of just one or a few genes and proteins. Therefore, methods which allow comprehensive interrogation of genetic pathways and networks hold great promise in delivering tumor-specific signatures, because expression levels of tens of thousands of genes can be monitored simultaneously. During the past few years microarray technology has emerged as the key tool in addressing pertinent clinical questions, the answers to which are critical for the realization of personalized genomic medicine, in which patients will be treated based on the biology of the tumor and the genetic profile."],["dc.identifier.doi","10.1007/s00761-010-1866-y"],["dc.identifier.isi","000281289000007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19377"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0947-8965"],["dc.title","Molecular markers for response prediction in locally advanced rectal cancer. Is individualized therapy coming?"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1359"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","International Journal of Colorectal Disease"],["dc.bibliographiccitation.lastpage","1367"],["dc.bibliographiccitation.volume","27"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Lorf, Thomas"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.date.accessioned","2018-11-07T09:05:22Z"],["dc.date.available","2018-11-07T09:05:22Z"],["dc.date.issued","2012"],["dc.description.abstract","Bilobar colorectal liver metastases (CRLM) are often considered incurable or associated with poor prognosis even after R0 resection. In this single-center study, we evaluate the impact of CRLM spreading on recurrence-free survival (RFS) and cancer-specific overall survival (CSS) after R0 resection of CRLM with respect to multimodal treatment strategies including perioperative chemotherapy and multistep resections. Between January 2001 and December 2010, R0 resection could be achieved in 70 patients with bilobar and 100 with unilobar CRLM. Extent of disease, perioperative chemotherapy, surgical procedures, adjuvant treatment, histopathological workup, RFS, and CSS were compared between both cohorts. Forty-six (66 %) patients with bilobar and 26 (26 %) patients with unilobar CRLM received preoperative chemotherapy (p < 0.001). For bilobar CRLM, more extended and multistep resection including portal vein occlusion were performed (29 % versus 3 %; p < 0.001). Morbidity (39 % versus 28 %, p = 0.183) and mortality (1 % versus 3 %, p = 0.644) rates were comparable in both patients' cohorts. Postoperative therapy was applied in adjuvant intent to 42 (60 %) versus 51 (51 %) patients (p = 0.275). The 5-year RFS and CSS rates were 24 % versus 31 % (p = 0.169) and 42 % versus 55 % (p = 0.131), respectively. To our single-center experience, there is no significant effect of CRLM spreading (bilobar versus unilobar) on RFS and CSS rates. Bilobar CRLM are more likely to require extended multimodal efforts to achieve R0 resection."],["dc.identifier.doi","10.1007/s00384-012-1455-1"],["dc.identifier.isi","000309171200014"],["dc.identifier.pmid","22430890"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8804"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25298"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0179-1958"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Bilobar spreading of colorectal liver metastases does not significantly affect survival after R0 resection in the era of interdisciplinary multimodal treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","380"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","VISZERALCHIRURGIE"],["dc.bibliographiccitation.lastpage","385"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Becker, H."],["dc.date.accessioned","2018-11-07T10:51:23Z"],["dc.date.available","2018-11-07T10:51:23Z"],["dc.date.issued","2007"],["dc.description.abstract","We report on a case of fibrolamellar carcinoma of the liver (FLC) of an 18-year-old female patient, which shows an uncommon growing pattern. Originated from the left liver lobe, it grows into the abdominal cavity descending to the umbilicus. The lesion could be removed in sano by atypical liver resection with a linear stapler. We give a review about literature concerning prognosis and therapy of FLC discussing it by means of our actual case."],["dc.identifier.doi","10.1055/s-2007-990463"],["dc.identifier.isi","000254585200008"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48879"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","1435-3067"],["dc.title","Fibrolamellar hepatocellular carcinoma - A rare tumor with uncommon growing pattern - A case report and review"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","75"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie"],["dc.bibliographiccitation.lastpage","78"],["dc.bibliographiccitation.volume","135"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Schulze, F. P."],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Becker, H."],["dc.contributor.author","Langer, C."],["dc.date.accessioned","2018-11-07T08:46:42Z"],["dc.date.available","2018-11-07T08:46:42Z"],["dc.date.issued","2010"],["dc.description.abstract","We report on the case of a 38-year-old male patient with a huge extramural gastrointestinal stromal tumour (GIST) of the stomach, located in the left upper and middle abdominal cavity that was diagnosed on the basis of a spontaneous rupture and consecutive haemoperitoneum. The lesion was resected completely in an emergency operation. The tumour was classified as a high-risk lesion for aggressive biological behaviour and with regard to tumour rupture with perforation of the serosa, an adjuvant systemic therapy was indicated."],["dc.identifier.doi","10.1055/s-0029-1224606"],["dc.identifier.isi","000276086000014"],["dc.identifier.pmid","19941267"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20756"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0044-409X"],["dc.title","Extramural Gastral GIST Manifested by Spontaneous Perforation with Acute Intraabdominal Bleeding and Haemoperitoneum"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.volume","31"],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Ghadirni, M."],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Langer, C."],["dc.date.accessioned","2018-11-07T11:18:52Z"],["dc.date.available","2018-11-07T11:18:52Z"],["dc.date.issued","2008"],["dc.format.extent","92"],["dc.identifier.isi","000253372800290"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55138"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","0378-584X"],["dc.title","Preoperative chemoradiotherapy in locally advanced rectal cancer (CUICC stages II and III): Influence of postsurgical tumor response parameters on prognosis"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]